Current and Future Considerations for the Use of Checkpoint Inhibitors in Gastroesophageal Cancers

Get an expert&rsquo s take on recent advances and current best practices in the use of immune checkpoint inhibitors for treating gastroesophageal cancers in this program that includes live workshops an on-demand Webcast and downloadable slideset.

Share

Program Content

Activities

<i>EP</i>: ICIs for GE Cancers
ExpressPoints: Current and Future Considerations for the Use of Checkpoint Inhibitors in Gastroesophageal Cancers
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: August 10, 2020

Expires: August 09, 2021

ICIs for GE Cancers
Current and Future Considerations for the Use of Checkpoint Inhibitors in Gastroesophageal Cancers
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: August 10, 2020

Expires: August 09, 2021

Activities

ICI in GEJ Cancers
Current and Future Considerations for the Use of Checkpoint Inhibitors in Gastroesophageal Cancers
Congratulations: You achieved a completion on 04/09/2022

Faculty

cover img faculity

Manish A. Shah, MD

Assistant Member, Department of Medicine, Gastrointestinal Oncology
Memorial Sloan-Kettering Cancer Center
Attending Physician, Department of Medicine, Division of Solidy Tumor Oncology
Memorial Hospital
New York, New York

cover img faculity

Zev A. Wainberg, MD

Co-Director, GI Oncology Program
Professor of Medicine and Surgery
Director, Early Phase Therapeutics
Jonsson Comprehensive Cancer Center
UCLA School of Medicine
Los Angeles, California

cover img faculity

Yelena Y. Janjigian, MD

Associate Attending Physician
Chief, 
Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

Provided by

ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Merck Sharp & Dohme Corp.